It will end in tiers: A strategy to include “dabblers” in the buprenorphine workforce after the X-waiver

Brendan Saloner, Barbara Andraka Christou, Adam J. Gordon, Bradley D. Stein

Research output: Contribution to journalComment/debatepeer-review

Abstract

Buprenorphine is one of the gold standard medication treatments for opioid use disorder (OUD), with proven effectiveness in preventing overdose, increasing abstinence, and improving quality of life. In the United States, buprenorphine can be legally prescribed and administered in office-based settings from clinicians who are specially credentialed to provide that care under the X-waiver. We believe the X-waiver will ultimately be repealed, but there is a need for a variety of strategies to create a new treatment system after the X-waiver. Building a new tier of treatment capacity will require educational outreach, systems strategies, and enhanced payments.

Original languageEnglish (US)
Pages (from-to)153-157
Number of pages5
JournalSubstance Abuse
Volume42
Issue number2
DOIs
StatePublished - 2021

Keywords

  • Buprenorphine
  • DATA 2000
  • access to care
  • policy
  • quality of care

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'It will end in tiers: A strategy to include “dabblers” in the buprenorphine workforce after the X-waiver'. Together they form a unique fingerprint.

Cite this